CLYM's share count plummeted 29% while cash burned at an accelerated rate, with operating cash flow deteriorating 249% amid a massive R&D spending surge.
The dramatic reduction in outstanding shares from 67.5M to 47.8M combined with accelerating cash burn creates a concerning picture of a company potentially forced into dilutive financing or asset sales. With cash declining 59% to $35.7M and operating cash flow worsening significantly, CLYM appears to be approaching a critical funding inflection point that could materially impact shareholder value.
CLYM's financial position deteriorated significantly with cash declining 59% to $35.7M while R&D expenses surged 230% to $46.7M, driving operating cash flow negative by $54.4M compared to $15.6M previously. Despite the massive increase in spending, net losses actually improved 19% to $59.9M, though this was offset by the company's shrinking asset base and stockholders' equity declining 24%. The combination of accelerating cash burn, reduced share count, and diminishing cash reserves signals potential liquidity constraints that may force difficult capital allocation decisions in the near term.
Operating cash flow fell 249.3% — earnings quality concerns; investigate working capital changes and non-cash items.
R&D investment increased 229.5% — signals commitment to future product development, though near-term margin impact.
Cash declined 59.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current liabilities surged 41.6% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 37% — significant increase in debt or obligations, assess impact on financial flexibility.
Current assets declined 31.7% — monitor working capital adequacy and short-term liquidity.
Equity decreased 24.3% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 22.8% — asset sales, write-downs, or balance sheet optimization underway.
Net income grew 19% — bottom-line growth signals improving overall business health.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →